Company Profile
Inhibikase Therapeutics Stock Price, News & Analysis
- Ticker:
- IKT
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- United States
Stock performance
1.96 USD (-3.92%)
Close
Last updated: July 13, 2026 at 00:00
269.35M USD
Market cap
Why the stock is moving
IKT is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Inhibikase Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Inhibikase Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Inhibikase Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Inhibikase Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent related feed items are shown below in reverse chronological order.
- 01
Zimmer Biomet Names Chintan Desai President of Asia Pacific Region
ZBH · Source: Zimmer Biomet
- 02
Inhibikase Therapeutics Announces Sale of $50 Million of Shares Through its At-the-Market (ATM) Facility
Source: Inhibikase Therapeutics
- 03
Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results
ZBH · Source: Zimmer Biomet
- 04
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma
BMY · Source: BMYBristol-Myers Squibb Company
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inhibikase Therapeutics (IKT)?
Inhibikase Therapeutics (IKT) most recently closed at 1.96 USD, a -3.92% move versus the previous session.
What is the market cap of Inhibikase Therapeutics (IKT)?
Inhibikase Therapeutics currently has a market capitalization of 269.35M USD on BioPharmSignal.
What does Inhibikase Therapeutics do?
Inhibikase Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is IKT stock listed?
Inhibikase Therapeutics (IKT) is associated with NASDAQ, United States, Biotechnology.
What is Inhibikase?
Inhibikase Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Inhibikase Therapeutics targeting with Inhibikase?
Inhibikase Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Inhibikase Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.